Over the past year, Pfizer has certainly achieved CEO Ian Read's goal of bulking up beyond best-selling vaccine Prevnar 13. In addition to ushering its meningitis B vaccine through the clinic to an FDA approval, it's made two pickups to expand its marketed portfolio and pipeline. So what's next for the pharma giant's vaccines unit? Perhaps more deals, its leader says.
After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case. Read more >>
Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like. Read more >>
POPULAR COMMENT THREADS
In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.
BCG (Bacille Calmette-Guérin) is the only WHO-approved tuberculosis vaccine and is given to infants, but has proven ineffective in adults. Enter GlaxoSmithKline, which, along with Aeras and Kenya Medical Research Institute, will roll their candidate in Phase IIb trials in Kenya.
Sanofi Pasteur counts pediatric vaccines among its 5 key areas, and it's bolstering its offerings in the field with Wednesday's FDA approval of the Quadracel vaccine.
Results from the Phase I trial of yet another experimental Ebola vaccine are in, but unlike other vaccines in the field, this one is based on the virus strain that caused the 2014 epidemic, and not an older one. The vaccine, developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology, is called a recombinant adenovirus type-5 vaccine.
In January, Germany's cost watchdog decided that Dendreon's--now Valeant's--Provenge had no added benefit for men with metastatic prostate cancer. But now, it's changing its tune.
From Our Sister Sites
In this week's EuroBiotech Report, Malin pulled in a blockbuster €330 million IPO, putting it among the biggest ever European biotech listings. Malin is targeting pre-IPO biotechs, a group that will find it easier to access public markets if a European equivalent of the JOBS Act, the U.S. legislative rethink that opened the current biotech IPO window, is passed. And more.
Hearing devices have not been among Medtronic's competencies--until now. The medical device giant has bought magnetic hearing implant startup Sophono for an undisclosed amount. Sophono's implant is the smallest and most effective at higher frequencies, according to the startup and Medtronic.